<DOC>
	<DOCNO>NCT01660815</DOCNO>
	<brief_summary>This study determine florbetapir ( 18F ) ( 18F-AV-45 ) radioactivity distribute throughout body Japanese subject .</brief_summary>
	<brief_title>A Study Florbetapir ( 18F ) Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Are Japanese cognitively normal healthy male female least 45 year age ; 2 . Give informed consent ; 3 . Are able lie still image table period one hour . 1 . Have radiation exposure ( PET , SPECT CT scan ) experimental purpose within last year ; 2 . Are claustrophobic otherwise unable tolerate imaging procedure ; 3 . Have medical condition surgical history would confound evaluation dosimetry ( e.g. , liver disease , colectomy etc . ) ; 4 . Have current clinically significant cardiovascular disease . Clinically significant cardiovascular disease usually include one following : 1. cardiac surgery myocardial infarction within last 6 month ; 2. unstable angina ; 3. coronary artery disease require change medication within last 3 month ; 4. decompensated congestive heart failure ; 5. significant cardiac arrhythmia conduction disturbance , particularly result atrial ventricular fibrillation , cause syncope , near syncope , alteration mental status ; 6. severe mitral aortic valvular disease ; 7. uncontrolled high blood pressure ; 8. congenital heart disease ; 9. clinically significant abnormal result ECG , include limited QTc &gt; 450 msec ; Before enrol patient evidence condition , investigator must contact sponsor ; 5 . Have current clinically significant medical comorbidities , indicate history , physical exam , laboratory evaluation might pose potential safety risk , interfere absorption metabolism study medication limit interpretation trial result . These include limited clinically significant hepatic , renal , pulmonary , metabolic endocrine disease , cancer ; 6 . Have history drug alcohol abuse within last year , prior prolonged history abuse ; 7 . Have history epilepsy convulsion , except febrile convulsion childhood ; 8 . Have clinically significant infectious disease , include AIDS HIV infection previous positive test hepatitis B , hepatitis C , HIV1 , HIV2 ; 9 . Have radiopharmaceutical imaging treatment procedure within 7 day prior study image session ; 10 . Are females childbearing potential surgically sterile , refrain sexual activity use reliable method contraception . Females childbearing potential must pregnant ( negative serum Î²HCG time screen ) breastfeed screen . Females must agree avoid become pregnant , must agree refrain sexual activity use reliable method contraception prescribe birth control IUD 24 hour follow administration florbetapir ( 18F ) ; 11 . Have history severe drug allergy hypersensitivity ; 12 . Received investigational medication within last 30 day participate clinical trial experimental medication last 30 day . Additionally , time last dose previous experimental medication enrollment ( completion screen assessment ) must least equal 5 time terminal halflife previous experimental medication ; 13 . Have know hypersensitivity alcohol ; 14 . In opinion investigator , otherwise unsuitable study type .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>